You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Non-Surgical Management of Advanced Hepatocellular Carcinoma

ID: GL 2-24 May 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
B.M. Meyers, , J. Knox,, R. Cosby,, R. Beecroft,, K. Chan,, N. Coburn,, J. Feld,, D. Jonker,, A. Mahmud,, J. Ringash, and the Gastrointestinal Disease Site Group

Guideline Objective

The objective of this guideline is to make recommendations regarding the non-surgical treatment of advanced hepatocellular carcinoma (HCC).

Patient Population

These recommendations apply to adults with locally advanced and advanced HCC, Barcelona Clinic Liver Cancer Stage B and higher, who are not suitable for transplant or surgery.

Intended Guideline Users

Intended users of the guideline are clinicians involved in the care of patients who have HCC; specifically, medical oncologists, radiation oncologists, interventional radiologists, hepatologists, and surgical oncologists.

Research Questions

  1. What are benefits of other local therapies (transarterial ethanol ablation [TEA], bland transarterial embolization [TAE], radiofrequency ablation [RFA], transarterial radioembolization [TARE], stereotactic body radiation therapy [SBRT] and drug eluting bead transarterial chemoembolization [DEB-TACE]) versus transarterial chemoembolization (TACE)?
  2. What is the benefit of the addition of sorafenib to local therapies (TEA, TAE, RFA, TARE, SBRT, TACE, DEB-TACE)
  3. What is the benefit of other systemic treatment regimens versus sorafenib?
  4. What is the benefit of the eradication of viral hepatitis (HCV and/or HBV) in patients with advanced HCC?
  5. What is the benefit of second-line systemic therapy following sorafenib?
  6. Is there a survival difference in HCV populations compared with HBV populations compared with non-viral populations when treated with sorafenib?
  7. Is there a survival difference in HCV populations compared with HBV populations compared with non-viral populations when treated with TACE, TAE, or TEA?
pdf download Summary (PDF) (185.05 KB)